Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Oligodendrocyte progenitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oligodendrocyte progenitor cells (OPCs), also known as oligodendrocyte precursor cells, NG2-glia or polydendrocytes, are a subtype of glial cells in the central nervous system. They are precursors to oligodendrocytes and may also be able to differentiate into neurons and astrocytes.
Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
Owner:CORNELL RES FOUNDATION INC
Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
ActiveUS20150352154A1Robust and reliable protocolSuitable for useBiocideSenses disorderDiseaseInduced pluripotent stem cell
The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations.
Owner:UNIVERSITY OF ROCHESTER
Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
InactiveUS8263402B1Easy to learnSignificant acceleration in the studyNervous disorderGenetically modified cellsProgenitorMixed Cellular Population
The present invention is directed to a method of separating oligodendrocyte cells or progenitor cells thereof from a mixed population of cells. It comprises selecting a promoter which functions only in the oligodendrocyte cells or progenitor cells thereof, introducing a nucleic acid molecule encoding a fluorescent protein under control of that promoter into the mixed population cells, allowing the oligodendrocyte cells or progenitor cells thereof to express the fluorescent protein, and separating the fluorescent cells from the mixed population cells, where the separated cells are the oligodendrocyte cells or progenitor cells thereof. The invention also relates to the isolated and enriched human oligodendrocyte cells or progenitor cells thereof.
Owner:CORNELL RES FOUNDATION INC
Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
ActiveUS20170183627A1Low costComparable myelination potentialNervous disorderNervous system cellsProgenitorInduced pluripotent stem cell
Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to 04+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.
Owner:NEW YORK STEM CELL FOUND
Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
ActiveUS20170198255A1Robust and reliable protocolSuitable for useSenses disorderNervous disorderDiseaseInduced pluripotent stem cell
The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations.
Owner:UNIVERSITY OF ROCHESTER
Differentiation method for production of glial cell populations
Owner:CASE WESTERN RESERVE UNIV
Method for differentiation of embryonic stem cells into nerve cells through in vitro induction
InactiveCN102899285APromote partial recoveryPromote regenerationNervous disorderMammal material medical ingredientsOLIG2Conceptus
The invention belongs to the field of biomedicine, and relates to a method for differentiation of embryonic stem cells into nerve cells through in vitro induction, especially to a method for induction of Olig2<+>-GFP<+>-mES nerve cell differentiation through a purine derivative Purmorphamine, and uses thereof. According to the present invention, an embryoid body mediated nerve induction method is adopted, Olig2-GFP<+>-mES is adopted as a cell model, a purine derivative Purmorphamine and all-trans retinoic acid are combined to carry out directed induction on the Olig2-GFP<+>-mES cells to obtain spinal motor neurons and oligodendrocyte progenitor cells through differentiation; experiment results show that the Purmorphamine can be used as a substitute of SHH, can effectively induce Olig2<+>-GFP<+>-mES differentiation to obtain high purity and function spinal motor neurons and oligodendroglial cells, and can cause expression changes of related genes; and transplant experiment results show that the induced nerve cells can promote partial function and morphology restoration after rat spinal cord injury, and have effects of spinal cord injury regeneration promotion and function reconstruction.
Owner:FUDAN UNIV
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
ActiveUS20140038949A1Enhances myelinationIncreased myelination of nervesBiocideSenses disorderDirected differentiationDemyelinating disease
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Owner:THE SCRIPPS RES INST +1
Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
The present invention relates to a method of modulating production of neurons and / or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and / or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.
Owner:CORNELL RES FOUNDATION INC
Oligodendrocyte precursor cells and method of obtaining and culturing the same
The invention describes a self-renewing, phenotypically homogeneous population of oligodendrocyte precursor cells having a synchronized developmental stage and methods of obtaining a self-renewing phenotypically homogeneous population of oligodendrocyte precursor cells. Other methods include methods of maintaining and storing a homogeneous population of oligodendrocyte precursor cells for a prolonged period of time without change in the characteristics of the cells and methods of dedifferentiating oligodendrocyte precursor cells. The self-renewing, phenotypically homogeneous population of oligodendrocyte precursor cells or homogeneous population of oligodendrocytes may be useful for treating a patient having a CNS disorder or condition.
Owner:OTSUKA PHARM CO LTD
Method for obtaining human OPCs and OPCs medium
The invention relates to a method for obtaining human OPCs (Oligodendrocyte Progenitor Cells) and an OPCs medium. According to the method, neural stem cells are used as a sorting source, the human OPCs can be obtained by separation through an immunomagnetic bead method, and a more economical medium suitable for OPCs in vitro culture and passage, so that a great amount of high-purity human OPCs can be obtained in a short time, and a new choice is provided for clinical application.
Owner:栾佐
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
ActiveUS9592288B2Enhances myelinationIncreased myelination of nervesSenses disorderNervous disorderDirected differentiationDemyelinating disease
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Owner:THE SCRIPPS RES INST +1
Differentiation culture medium and preparation method of oligodendrocyte progenitor cells
ActiveCN108624560AImprove antioxidant capacityIncrease vitalityNervous disorderCulture processProgenitorOligodendrocyte progenitor
The invention provides a culture medium for differentiating neural stem cells into oligodendrocyte progenitor cells. The culture medium does not contain exogenous factors, so that pollution of the exogenous factors is avoided, and the oligodendrocyte progenitor cells can be efficiently differentiated. The invention further provides a method for preparing the oligodendrocyte progenitor cells by using the culture medium. By use of the method provided by the invention, the differentiation efficiency of the oligodendrocyte progenitor cells is improved on the premise of increasing the yield of theoligodendrocyte progenitor cells.
Owner:HELP STEM CELL INNOVATIONS CO LTD
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
ActiveUS20160166687A1Enhances myelinationIncreased myelination of nervesBiocideSenses disorderDirected differentiationDemyelinating disease
Owner:THE SCRIPPS RES INST +1
Application of shikimic acid in preparing drug for preventing or treating demyelinating diseases
InactiveCN108379246APromote differentiation and maturationSolve the problem of regeneration failureNervous disorderAnhydride/acid/halide active ingredientsMyelin sheathsRemyelination
The invention discloses application of shikimic acid in preparing a drug for preventing or treating demyelinating diseases. In studying the effect of the shikimic acid in preventing or treating the demyelinating diseases, it is found that the shikimic acid can alleviate the severity of an inflammatory mouse demyelinating disease model induced by myelin sheath oligodendrocyte glycoprotein, improvethe demyelination lesion conditions of a focal mouse spinal cord demyelinating model induced by lysoph-osphatidylcholine, and accelerate remyelination and reduce the demyelination size by promoting oligodendrocyte progenitor cells to be differentiated into mature oligodendrocytes. As is shown by all above, the shikimic acid has a great application prospect in clinical treatment of the demyelinating diseases.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells from somatic cells and use thereof
ActiveUS20170058258A1Efficient preparationNervous disorderPeptide/protein ingredientsTransdifferentiationOLIG2
The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.2, a nucleic acid molecule coding the protein, or a vector including the nucleic acid molecule introduced thereinto; a pharmaceutical composition for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for treating spinal cord injuries or demyelination diseases; a composition for screening drugs for the treatment of spinal cord injuries or demyelination diseases; a 3D printing biomaterial composition for manufacturing artificial tissues for the treatment of spinal cord injuries or demyelination diseases; and a method for direct transdifferentiation into oligodendrocyte progenitor cells from somatic cells. According to the present invention, the oligodendrocyte progenitor cells are prepared from somatic cells through direct transdifferentiation, and thus can be favorably utilized for the treatment of spinal cord injuries and demyelination diseases.
Owner:UNIST ULSAN NAT INST OF SCI & TECH
Development of oligodendrocyte progenitor cells prepared by differentiating mesenchymal stem cells through eleutheroside and kit, and medicine for nerve system disease
InactiveCN102337246AHigh selectivityHigh purityNervous disorderNervous system cellsDiseaseNervous system
The invention provides a differential medium for obtaining oligodendrocyte progenitor cells and proliferation thereof by processing mesenchymal stem cells through eleutheroside. The differential medium comprises a liquid basal medium, and also comprises 1-100ug / mL eleutheroside, 1 to 20 percent of fetal calf serum, 5 to 300ng / mL human epidermal growth factor (EGF) and 5 to 300ng / mL basic fibroblast growth factor (bFGF) based on the volume of the liquid basal medium. The invention also provides a method for preparing an eleutheroside processing kit by using the differential medium, and also provides a medicinal composition comprising the oligodendrocyte progenitor cells prepared by the method and used for treating nerve system disease. By using the differential medium, the method has the advantages that: the mesenchymal stem cells can be efficiently differentiated and the oligodendrocyte progenitor cells are obtained. The medicinal composition for treating diseases such as traumatic spinal cord injury, multiple sclerosis and the like can repair injured nerve cells in vivo and eliminate neurologic disorder.
Owner:北京弘润天源基因生物技术有限公司
Preparation method of human oligodendrocyte precursor cell inhibiting nerve secondary injury, kit and application thereof
ActiveCN106011173AInhibition of secondary damageProtect physiological functionNervous disorderNeuregulinsVirus typeGlial Growth Factor
The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.
Owner:江西美奥生物技术有限公司
Methods for promoting oligodendrocyte regeneration and remyelination
PendingUS20190099452A1Nervous disorderMicrobiological testing/measurementOligodendrocyte differentiationDemyelinating disease
The present invention provides a method for preventing or treating a demyelinating disease in a subject. Also provided herein is a method for reducing demyelination, inducing remyelination, promoting oligodendroglial progenitor cell (OPC) proliferation, and / or promoting oligodendrocyte differentiation in a subject. Kits are also described herein.
Owner:SHRINERS HOSPITALS FOR CRIPPLED CHILDREN +1
Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
ActiveUS8513009B2Good reproducibilityReduce Potential ContaminationBioreactor/fermenter combinationsBiological substance pretreatmentsSerum free mediaChemical composition
Owner:ASTERIAS BIOTHERAPEUTICS INC
Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
ActiveUS20200231932A1Increase the number ofEasy to distinguishCulture processNervous system cellsNeuroectodermMorphogen
Methods for differentiating human pluripotent stem cells to dorsal neuroectoderm progenitors and further to glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK / ERK signaling are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs in the absence of the ventralizing morphogen SHH or a SHH signaling activator. The methods of the present disclosure reproducibly produce dorsal neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.
Owner:ASTERIAS BIOTHERAPEUTICS INC
Differentiation and amplification method for inducing human neural stem/progenitor cells to differentiate into oligodendrocyte progenitor cells and application thereof
InactiveUS20150093761A1Avoid security risksSafe and effectiveNervous system cellsArtificial cell constructsDiseaseProgenitor
A Method for inducing human neural stem / progenitor cells to differentiate into oligodendrocyte progenitor cells and application thereof comprises following steps of: pre-treating neural stem cells derived from different resources in pre-treatment medium including bFGF and EGF for culturing; and inducing neural stem cells after pre-treating with inducing medium including PDGF-AA, bFGF and NT3, so as to differentiate into oligodendrocyte progenitor cells (OPCs). Main markers of the OPCs obtained by the method, such as NG2, O4, A2B5 and PDGFR, have a positive rate of 80˜90%. The OPCs obtained thereby is capable of proliferating steadily in the OPCs inducing medium for at least 10 generations and simultaneously maintaining biological characteristics thereof unchanged. The OPCs induced by the present invention can be applied in treating myelin-associated diseases or researching on drug screening.
Owner:LUAN ZUO
Modulating the production of neurons and/or oligodendrocytes from white matter progenitor cells
The present invention relates to a method of modulating production of neurons and / or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and / or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.
Owner:CORNELL RES FOUNDATION INC
Culture medium, induction culture method of oligodendrocyte progenitor cells and application
PendingCN113481161AShorten the scheduleAvoid cumbersomeNervous disorderCulture processPluripotential stem cellOligodendrocyte progenitor
The invention provides a culture medium, an induction culture method of oligodendrocyte progenitor cells and application. The culture medium combination provided by the invention comprises the following culture medium in the induced differentiation stage: embryonic bodies, neural epithelial cells, Pre-OPCs and hOPCs. In each stage, a specific induction culture medium is adopted for adherent culture. Experimental results show that the induction rate of differentiation of hESC and hiPSC to hOPC can be remarkably increased, the purity of hOPC is obviously improved, and the induction time is greatly shortened compared with that of traditional suspension culture. The induction culture method is suitable for differentiation of human embryonic stem cells and human induced pluripotent stem cells to oligodendrocyte progenitor cells. Experiments show that OPC obtained through induction culture can obviously reduce the loss of injured brain region tissues, can improve and enhance the recovery of the injured brain region tissues, and can be used for cell transplantation to treat cerebral nervous system diseases such as cerebral apoplexy injury.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL
Methods for directing differentiation of clonogenic neural stem cells with coumarins
A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-β-D-glucopyranoside. The coumarin compounds showed significant activity of directing the differentiation of NSCs in pharmacological test and thereof could be used to prepare drugs to direct NSCs differentiated to oligodendrocyte progenitor cells (OPCs) for the treatment of demyelinating diseases or spinal cord injury. The drug could be a pure coumarin compound or a pharmaceutical composition comprising a therapeutical dose of a coumarin compound as active ingredients and a pharmaceutically-acceptable carrier. The content of the active ingredients in the pharmaceutical composition is between 0.1% and 99.5% by weight.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
ActiveUS10301592B2Low costComparable myelination potentialNervous disorderNervous system cellsProgenitorInduced pluripotent stem cell
Owner:NEW YORK STEM CELL FOUND INC
Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
InactiveUS20080206209A1Widespread and high-efficiency myelinationSlowed expansion with timeAntibacterial agentsBiocideProgenitorForebrain
One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.
Owner:CORNELL RES FOUNDATION INC
A preparation method, kit and application of human oligodendrocyte progenitor cells that inhibit secondary nerve injury
ActiveCN106011173BInhibition of secondary damageProtect physiological functionNervous disorderNeuregulinsGlial Growth FactorTherapeutic effect
The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.
Owner:江西美奥生物技术有限公司
Application of genetically modified oligodendrocyte progenitor cells in multiple sclerosis
ActiveCN113699117APromote generationGood treatment effectChemokinesGenetically modified cellsMS multiple sclerosisMyelin sheath
The invention discloses genetically modified oligodendrocyte progenitor cells and a preparation method and application thereof. The invention provides a method capable of simultaneously repairing a myelin sheath, promoting the generation of the myelin sheath and reducing inflammatory response and the autoimmune injury. In the method, the genetically modified oligodendrocyte progenitor cells are adopted; through transplantation of the genetically modified oligodendrocyte progenitor cells, direct repair of the myelin sheath is implemented, inflammatory response of nerves is relieved, and neurological functions are improved. The genetically modified oligodendrocyte progenitor cells have very good application prospect in clinical treatment of multiple sclerosis.
Owner:ALLIFE MEDICINE(BEIJING) LTD
Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
PendingCN109715175AImprove upper limb motor functionNervous disorderPharmaceutical delivery mechanismMedicineBiochemistry
Methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury are disclosed.
Owner:ASTERIAS BIOTHERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com